nimacimab glp-1 news A first-in-class antisense oligonucleotide — RES-010 (Resalis Therapeutics, Turin, Italy) — may complement and enhance the efficacy of antiobesity drugs such as receptor agonists (RAs), preclinical experiments and an ongoing phase February 2025: Obesity & Weight
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18























